BR112016015701A2 - Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel - Google Patents

Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel

Info

Publication number
BR112016015701A2
BR112016015701A2 BR112016015701A BR112016015701A BR112016015701A2 BR 112016015701 A2 BR112016015701 A2 BR 112016015701A2 BR 112016015701 A BR112016015701 A BR 112016015701A BR 112016015701 A BR112016015701 A BR 112016015701A BR 112016015701 A2 BR112016015701 A2 BR 112016015701A2
Authority
BR
Brazil
Prior art keywords
amino acid
acid residues
fibrinogen
functional amino
hydrogel
Prior art date
Application number
BR112016015701A
Other languages
English (en)
Inventor
Zbozien Renata
Original Assignee
Haemostatix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haemostatix Ltd filed Critical Haemostatix Ltd
Publication of BR112016015701A2 publication Critical patent/BR112016015701A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

DENDRÍMEROS DE PEPTÍDEO COMPREENDENDO OS PÉPTIDOS DE LIGAÇÃO DE FIBRINOGÊNIO. Os dendrímeros de peptídeo e os agentes são descritos, que podem ser usados para a polimerização de fibrinogênio e como agentes hemostáticos. Os dendrímeros de peptídeo compreendem um núcleo ramificado e uma pluralidade de peptídeos de ligação de fibrinogênio anexados separadamente de forma covalente ao núcleo ramificado. O núcleo ramificado compreende: i) de dois a dez resíduos de aminoácidos multi-funcionais, em que cada um peptídeo de ligação de fibrinogênio é separadamente de forma covalente anexado a um resíduo de amino ácido multi-funcional do núcleo ramificado; il) uma pluralidade de resíduos de aminoácidos multi-funcionais, em que um ou mais peptídeos de ligação de fibrinogênio são anexados separadamente de forma covalente a cada um dentre pelo menos dois resíduos de aminoácidos multi-funcionais adjacentes do núcleo ramificado; Hi) uma pluralidade de resíduos de aminoácidos multi-funcionais, em que dois ou mais peptídeos de ligação de fibrinogênio são anexados separadamente de forma covalente a pelo menos um dentre os resíduos de aminoácidos multi-funcionais do núcleo ramificado; iv) uma pluralidade de resíduos de aminoácidos multi-funcionais, em que dois ou mais resíduos de aminoácidos multi-funcionais são covalentemente ligados através de uma cadeia lateral de um resíduo de amino ácido adjacente multifuncional; ou y) um único resíduo de aminoácido multi-funcional e um peptídeo de ligação de fibrinogênio é anexado separadamente de forma covalente a cada grupo funcional do resíduo de aminoácido multi-funcional. Os resíduos de aminoácidos multi-funcionais compreendem os resíduos de aminoácidos tri- ou tetra-funcionais, ou resíduos de aminoácidos de tri- e tetra-funcionais,ou o único resíduo de aminoácido multi-funcional é um resíduo de aminoácido tri- ou tetra-funcional.
BR112016015701A 2014-01-08 2015-01-08 Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel BR112016015701A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1400292.7A GB201400292D0 (en) 2014-01-08 2014-01-08 Peptide dendrimers and agents
PCT/GB2015/050024 WO2015104544A1 (en) 2014-01-08 2015-01-08 Peptide dendrimers comprising fibrinogen-binding peptides

Publications (1)

Publication Number Publication Date
BR112016015701A2 true BR112016015701A2 (pt) 2017-10-03

Family

ID=50191056

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016015701A BR112016015701A2 (pt) 2014-01-08 2015-01-08 Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel

Country Status (17)

Country Link
US (1) US10994047B2 (pt)
EP (1) EP3092011B1 (pt)
JP (1) JP6717747B2 (pt)
KR (1) KR102410065B1 (pt)
CN (1) CN105916524B (pt)
AU (1) AU2015205438B2 (pt)
BR (1) BR112016015701A2 (pt)
CA (1) CA2935888A1 (pt)
ES (1) ES2848031T3 (pt)
GB (1) GB201400292D0 (pt)
HR (1) HRP20210184T1 (pt)
IL (1) IL246611A0 (pt)
MX (1) MX370174B (pt)
PH (1) PH12016501308A1 (pt)
RU (1) RU2719562C2 (pt)
SG (1) SG11201605581UA (pt)
WO (1) WO2015104544A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
RU2019109944A (ru) 2016-10-06 2020-11-06 Матоук Холдингс Лимитед Противомикробные композиции
WO2018065789A1 (en) 2016-10-06 2018-04-12 Matoke Holdings Limited Antimicrobial compositions
CN107625968B (zh) * 2017-09-20 2020-09-29 四川大学 一种肿瘤特异性组织-细胞双渗透纳米粒、制备方法及其应用
WO2019134982A1 (en) * 2018-01-04 2019-07-11 Amryt Research Limited Betulin-containing birch bark extracts and their formulation
CA3054228A1 (en) 2018-09-06 2020-03-06 Intercontinental Exchange Holdings, Inc. Multi-signature verification network
CN110448719B (zh) * 2019-06-28 2020-05-22 浙江大学 一种促进凝血的丝素-多肽电纺膜及其制备方法
KR20220161384A (ko) * 2020-03-31 2022-12-06 가부시끼가이샤 쓰리디 매트릭스 조사에 의한 자기 조립 펩티드의 멸균
US11666682B2 (en) * 2020-08-31 2023-06-06 Ethicon, Inc. Method of stopping CSF leaks and apparatus therefor
CN112206307B (zh) * 2020-09-15 2023-12-05 广州领晟医疗科技有限公司 一种可注射的温敏型水凝胶及其制备方法与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017633A1 (en) 1994-12-07 1996-06-13 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
CN1222918A (zh) * 1996-06-21 1999-07-14 曾尼卡有限公司 细胞粘连抑制剂
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
FR2813080B1 (fr) * 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
US6506365B1 (en) 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
US7550282B2 (en) 2002-11-20 2009-06-23 Bar-Ilan University Biological glue based on thrombin-conjugated nanoparticles
CA2530032C (en) 2003-06-16 2015-11-24 Loma Linda University Medical Center Deployable multifunctional hemostatic agent
JP2008507362A (ja) 2004-07-22 2008-03-13 ヘモ ナノサイエンス リミテッド ライアビリティ カンパニー 過剰な出血を処置するための組成物および方法
GB0516091D0 (en) * 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
GB0623607D0 (en) * 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
US20100021527A1 (en) 2008-07-25 2010-01-28 Chunlin Yang Collagen-related peptides and uses thereof and hemostatic foam substrates
US20130310853A1 (en) 2009-01-09 2013-11-21 Abbott Cardiovascular Systems Inc. Method and apparatus for percutaneous treatment of a blood vessel
WO2011006069A1 (en) * 2009-07-09 2011-01-13 Georgia Tech Research Corporation Peptides for binding fibrinogen and fibrin
GB201101740D0 (en) * 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding
EP2582051A1 (en) 2011-10-13 2013-04-17 ST-Ericsson SA Multi-level sigma-delta ADC with reduced quantization levels
GB201201751D0 (en) * 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing

Also Published As

Publication number Publication date
MX370174B (es) 2019-12-04
AU2015205438B2 (en) 2018-11-08
SG11201605581UA (en) 2016-08-30
EP3092011A1 (en) 2016-11-16
MX2016008876A (es) 2016-12-02
CN105916524B (zh) 2021-07-20
ES2848031T3 (es) 2021-08-05
CN105916524A (zh) 2016-08-31
KR20160105820A (ko) 2016-09-07
GB201400292D0 (en) 2014-02-26
US20160324977A1 (en) 2016-11-10
PH12016501308A1 (en) 2016-08-15
AU2015205438A1 (en) 2016-08-11
KR102410065B1 (ko) 2022-06-16
RU2719562C2 (ru) 2020-04-21
US10994047B2 (en) 2021-05-04
EP3092011B1 (en) 2020-11-18
JP2017505298A (ja) 2017-02-16
HRP20210184T1 (hr) 2021-04-30
RU2016130448A (ru) 2018-02-16
WO2015104544A1 (en) 2015-07-16
CA2935888A1 (en) 2015-07-16
JP6717747B2 (ja) 2020-07-01
IL246611A0 (en) 2016-08-31
RU2016130448A3 (pt) 2018-06-25

Similar Documents

Publication Publication Date Title
BR112016015701A2 (pt) Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
BR112018007017A2 (pt) polipeptídeos
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
CL2014003110A1 (es) Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
CR20150326A (es) Inhibidores de autotaxina
EA201500207A1 (ru) Гетероароматические соединения в качестве ингибиторов втк
NI201400032A (es) Piridopirazinas anticancerígenas via la
NI201500024A (es) Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis.
CL2014002077A1 (es) Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
BR112016030424A2 (pt) construções de anticorpo multiespecíficas
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
BR112014017021A2 (pt) inibidores de irak e usos dos mesmos
BR112017015833A2 (pt) compostos anti-senescência e usos dos mesmos
BR112018004246A2 (pt) combinação que compreende oligonucleotídeos imunoestimulantes
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
EA201491613A1 (ru) Катионные полимеры на основе гликогена
DOP2018000128A (es) Polipéptidos que inhiben cd40l
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01), A61L 15/32 (2006.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]